DENIS , Marc

The assessment of minimal residual disease (MRD) from blood samples of patients with resected non‐small cell lung carcinoma (NSCLC) is promising and opens up many opportunities for the optimisation of patient care in daily practice. Notably, this includes the potential for escalation or de‐escalation of adjuvant therapies. Thus, the evaluation...